BR0114846A - Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h - Google Patents

Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h

Info

Publication number
BR0114846A
BR0114846A BR0114846-0A BR0114846A BR0114846A BR 0114846 A BR0114846 A BR 0114846A BR 0114846 A BR0114846 A BR 0114846A BR 0114846 A BR0114846 A BR 0114846A
Authority
BR
Brazil
Prior art keywords
crystals
type
nateglinide
substantially free
producing nateglinide
Prior art date
Application number
BR0114846-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michito Sumikawa
Makoto Maruo
Kazuo Miyazaki
Shigehiro Nishina
Yukiko Matsuzawa
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BR0114846A publication Critical patent/BR0114846A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0114846-0A 2000-10-24 2001-10-23 Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h BR0114846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (1)

Publication Number Publication Date
BR0114846A true BR0114846A (pt) 2004-02-25

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114846-0A BR0114846A (pt) 2000-10-24 2001-10-23 Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h

Country Status (18)

Country Link
US (2) US20030229249A1 (enExample)
EP (1) EP1334964B1 (enExample)
JP (1) JP4225057B2 (enExample)
KR (1) KR100810930B1 (enExample)
CN (1) CN100422143C (enExample)
AT (1) ATE370115T1 (enExample)
AU (1) AU2001296001A1 (enExample)
BR (1) BR0114846A (enExample)
CA (1) CA2426745C (enExample)
CY (1) CY1106839T1 (enExample)
DE (1) DE60130014T2 (enExample)
DK (1) DK1334964T3 (enExample)
ES (1) ES2288997T3 (enExample)
MX (1) MXPA03003575A (enExample)
PT (1) PT1334964E (enExample)
RU (1) RU2275354C2 (enExample)
TW (1) TWI293290B (enExample)
WO (1) WO2002034713A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357719A1 (en) * 2000-03-17 2004-07-26 Ajinomoto Co, Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
CN1273442C (zh) * 2000-10-18 2006-09-06 味之素株式会社 酰基苯丙氨酸的制备方法
MXPA03003484A (es) * 2000-10-18 2003-07-14 Ajinomoto Kk Procedimiento para producir cristales de nateglinida.
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
AU2001296000A1 (en) * 2000-10-24 2002-05-27 Ajinomoto Co., Inc. Nateglinide-containing hydrophilic drug preparations
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
JP2006511614A (ja) * 2002-07-18 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形性形状
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
DE60310734T2 (de) * 2003-11-26 2007-10-11 A.M.S.A. Anonima Matèrie Sintètiche e Affini S.p.A. Verfahren zur Herstellung von Nateglinid in der B-Form
CN1950331A (zh) * 2004-05-07 2007-04-18 特瓦制药工业有限公司 那格列奈的多晶型物
US20070231393A1 (en) * 2004-05-19 2007-10-04 University Of South Carolina System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
AU2013257708A1 (en) * 2012-05-08 2014-12-04 Cellixbio Private Limited Compositions and methods for the treatment of diabetes
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
ES2797624T3 (es) 2012-05-23 2020-12-03 Cellix Bio Private Ltd Composición para el tratamiento de la enfermedad inflamatoria intestinal
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
DK3242869T3 (da) 2015-01-06 2022-01-31 Cellix Bio Private Ltd Sammensætninger og fremgangsmåder til behanding af inflammation og smerte
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
DE10199058I2 (de) 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
CN1245158C (zh) * 1996-11-15 2006-03-15 味之素株式会社 片剂组合物
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
SK9292002A3 (en) * 1999-12-28 2002-10-08 Ajinomoto Kk Oral preparations for diabetes
PL357719A1 (en) * 2000-03-17 2004-07-26 Ajinomoto Co, Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
MXPA03003484A (es) * 2000-10-18 2003-07-14 Ajinomoto Kk Procedimiento para producir cristales de nateglinida.
CN1273442C (zh) * 2000-10-18 2006-09-06 味之素株式会社 酰基苯丙氨酸的制备方法
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
EP1334964A1 (en) 2003-08-13
AU2001296001A1 (en) 2002-05-06
TWI293290B (enExample) 2008-02-11
DE60130014D1 (de) 2007-09-27
US20030229249A1 (en) 2003-12-11
CN1483018A (zh) 2004-03-17
RU2275354C2 (ru) 2006-04-27
ATE370115T1 (de) 2007-09-15
EP1334964B1 (en) 2007-08-15
EP1334964A4 (en) 2005-09-28
JPWO2002034713A1 (ja) 2004-03-04
CA2426745A1 (en) 2003-04-23
KR20030059212A (ko) 2003-07-07
CN100422143C (zh) 2008-10-01
DE60130014T2 (de) 2008-05-08
KR100810930B1 (ko) 2008-03-10
DK1334964T3 (da) 2007-09-24
MXPA03003575A (es) 2003-07-14
PT1334964E (pt) 2007-09-20
US20070232829A1 (en) 2007-10-04
ES2288997T3 (es) 2008-02-01
CY1106839T1 (el) 2012-05-23
JP4225057B2 (ja) 2009-02-18
CA2426745C (en) 2009-09-15
US7544834B2 (en) 2009-06-09
WO2002034713A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
BR0114846A (pt) Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h
BR0008050A (pt) Processo e dispositivo para filtração emcontracorrente
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
BR9711861A (pt) Processo para a fabrica-Æo de uma composi-Æo detergente por um processo sem a utiliza-Æo de torre
PT1144368E (pt) Sulfonamidas acetilenicas de acidos hidroxamicos baseados em alfa-aminoacidos como inibidores de tace
BRPI0308385A8 (pt) processo para purificar uma composição compreendendo ácido (met)acrílico, aparelho para produzir ácido (met)acrílico e aparelho para polimerizar ácido (met)acrílico
BR0311674A (pt) processo para a preparação de compostos
BR0303196A (pt) Suporte de montagem de uma extremidade frontal de um veìculo automotor e processo para a fixação destacável de um módulo de refrigeração em um suporte de montagem de uma extremidade frontal
CO5200765A1 (es) Nuevos androgenos oralmente activos que son derivados de delta 14 nandrolona 7 alfa - sustituidos
BRPI0400375A (pt) Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo
DE50101929D1 (de) Dermales applikationssystem für aminolävulinsäure
AR048279A1 (es) La forma ii cristalina de cabergolina
BR9915714A (pt) Remoção de silicatos dissolvidos de solventes da sìntese direta de álcool-silìcio
EP1636176A4 (en) POLYMORPHIC FORM A OF 4 -6-ACETYL-3-¬3- (4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO) PROPOXY-2-PROPYLPHENOXY BUTTERIC ACID
BR0108912A (pt) Processamento de material por expansão-contração de solvente repetido
DE50107209D1 (de) Verfahren zur herstellung von 5-aminosalicylsäure
BR0312604A (pt) ácidos imido-alcanpercarboxìlicos, composições, e, processo para a preparação e uso de ácidos imido-alcanpercarboxìlicos
AR036018A1 (es) Proceso para aislar monohidrato de imipenem cristalino puro
BR9711971A (pt) Processo para a produ-Æo de difluometano
BR0205164A (pt) Processo para purificar azeotropicamente material orgânico polimerizável aquoso
BR9909029A (pt) Estabilização de poliisocianatos orgânicos
BR0112820A (pt) Processo para a preparação de (alfa) clorocetonas
ATE259279T1 (de) Mechanisches werkzeug zum entfernen von muttern und bolzen
ATE423106T1 (de) Verfahren zur kristallisation von n-(1(s)- ethoxycarbonyl-3-phenylpropyl)-l-alanin n- carbonsäureanhydrid
AR034084A1 (es) Proceso para la remocion de dimetil eter en la sintesis de sevoflurano.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2274 DE 05/08/2014

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.